---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-052733"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2025-05-27T23:59:59+00:00"
generated_at: "2026-05-20T10:21:50.480579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025

## Summary
- Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.
- Trial is randomized, double-blind, placebo-controlled; endpoints include safety and lung function (FVC).
- Topline data from the REVERT IPF trial is anticipated in the fourth quarter of 2025.
- TTI-101 targets STAT3, a central mediator of fibrotic signaling pathways.

## SEC filing metadata
- accession: 0001104659-25-052733
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2025-05-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/0001104659-25-052733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465925052733/tm2516173d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-052733
- JSON: https://secwatch.observer/filing/0001104659-25-052733.json
- Plain text: https://secwatch.observer/filing/0001104659-25-052733.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.